scholarly article | Q13442814 |
P50 | author | Grazyna Kochan | Q28037218 |
Stefan Knapp | Q40296391 | ||
Hugo Arasanz | Q57570957 | ||
María Isabel Zudaire | Q73670801 | ||
Joaquín Fernández-Irigoyen | Q79802305 | ||
David Guerrero-Setas | Q84440422 | ||
P2093 | author name string | Noelia Casares | |
Apirat Chaikuad | |||
David Escors | |||
Enrique Santamaría | |||
Therese Liechtenstein | |||
Teresa Lozano | |||
Idoia Blanco-Luquin | |||
Maria Gato-Cañas | |||
Xabier Martinez de Morentin | |||
P2860 | cites work | Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells | Q24658240 |
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells | Q28242808 | ||
Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification | Q29547200 | ||
STRING v9.1: protein-protein interaction networks, with increased coverage and integration | Q29614691 | ||
Andromeda: a peptide search engine integrated into the MaxQuant environment | Q29615816 | ||
Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics | Q33996767 | ||
Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function | Q34087816 | ||
The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells | Q34310345 | ||
Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. | Q34326806 | ||
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice | Q34365909 | ||
Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays | Q34456201 | ||
Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis | Q34616787 | ||
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity | Q34654430 | ||
Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer | Q34956969 | ||
Classification of current anticancer immunotherapies | Q35149637 | ||
Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice | Q35648172 | ||
Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis | Q35651689 | ||
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer | Q35828574 | ||
Proapoptotic BID is required for myeloid homeostasis and tumor suppression | Q35963747 | ||
Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer | Q36544980 | ||
Effects of notch signaling on regulation of myeloid cell differentiation in cancer | Q37456808 | ||
Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. | Q37894790 | ||
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. | Q38959137 | ||
Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts | Q39103952 | ||
MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. | Q39356550 | ||
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis | Q39641093 | ||
Targeting dendritic cell signaling to regulate the response to immunization | Q40027559 | ||
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy | Q42124738 | ||
Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells | Q42840029 | ||
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells? | Q42910288 | ||
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model | Q43243177 | ||
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. | Q44419395 | ||
Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes | Q45866161 | ||
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. | Q54421148 | ||
P4510 | describes a project that uses | limma | Q112236343 |
RTCA | Q114077291 | ||
P433 | issue | 29 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 27160-27175 | |
P577 | publication date | 2015-07-23 | |
P1433 | published in | Oncotarget | Q1573155 |
P1476 | title | A core of kinase-regulated interactomes defines the neoplastic MDSC lineage | |
P478 | volume | 6 |
Q50041869 | Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. |
Q90300272 | Decoding communication patterns of the innate immune system by quantitative proteomics |
Q65000057 | ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. |
Q47550777 | Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections. |
Q40385399 | Myeloid-Derived Suppressor Cells |
Q48293607 | Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment |
Q48215791 | Myeloid-derived suppressor cells coming of age. |
Q47563950 | Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells |
Q38824190 | Novel immunotherapies for the treatment of melanoma. |
Q64085542 | PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer |
Q40062424 | PD1 signal transduction pathways in T cells. |
Q88081063 | Plasticity of myeloid-derived suppressor cells in cancer |
Q92285420 | Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring |
Q92132117 | Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? |
Q64914890 | The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. |
Q57067759 | The intracellular signalosome of PD-L1 in cancer cells |
Q47103744 | The paradoxical role of tumor-infiltrating immune cells in lung cancer |
Q89587297 | Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment |
Q92787500 | Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment |
Search more.